NASDAQ:IMCR Immunocore Q3 2025 Earnings Results & Report $29.39 +1.05 (+3.71%) As of 03:05 PM Eastern This is a fair market value price provided by Massive. Learn more. Immunocore beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of $0.0210 versus the -$0.30 consensus estimate, while revenue of $103.69 million fell short of the $137.29 million estimate by $33.60 million. Revenue increased 29.2% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call4:00 PM ET Immunocore EPS ResultsActual EPS$0.0210Consensus EPS -$0.30Beat/MissBeat by +$0.3210One Year Ago EPS$0.17EPS Beat Rate6 of last 8 quartersImmunocore Revenue ResultsActual Revenue$103.69 millionExpected Revenue$137.29 millionBeat/MissMissed by -$33.60 millionYoY Revenue Growth+29.20%Upcoming EarningsImmunocore's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Immunocore Q3 2025 Earnings FAQ Did Immunocore beat earnings estimates for Q3 2025? Immunocore (NASDAQ:IMCR) reported earnings of $0.0210 per share for Q3 2025, beating the consensus estimate of -$0.30. The report was announced on Thursday, November 6, 2025. What was Immunocore's revenue for Q3 2025? Immunocore reported revenue of $103.69 million for Q3 2025, against a consensus estimate of $137.29 million. When is Immunocore's next earnings date? Immunocore's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunocore on the company's earnings history page. Immunocore Earnings HeadlinesImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesOctober 15 at 7:00 AM | globenewswire.comImmunocore Holdings stock hits 52-week low at 27.5 USDOctober 14 at 7:23 PM | ca.investing.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel CrucialSeptember 29, 2026 | seekingalpha.comImmunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comImmunocore Completes Enrollment in Study of Potential Advanced Melanoma TreatmentSeptember 14, 2026 | finance.yahoo.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapies designed to treat cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and redirect the patient’s T cells to destroy those cells. The company’s lead product, KIMMTRAK (tebentafusp-tebn), is a bispecific TCR therapy approved in the United States and Europe for certain adults with unresectable or metastatic uveal melanoma, a rare form of eye cancer. Immunocore is also developing additional ImmTAC medicines for other solid tumors, hematologic cancers, infectious diseases and autoimmune conditions. Founded in 2008 and headquartered in Abingdon, England, Immunocore serves international markets through its commercial and development operations in the United States and Europe, as well as through global clinical and regulatory activities. The company is led by Chief Executive Officer Bahija Jallal.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
